Reference: GILA/PB/P02/2608
Company stage: PE-backed / Pre-IPO
Seat classification: Contractually independent, non-executive private-company board seat; final statutory classification to be confirmed before appointment
Primary board geography: Hyderabad with vaccine plants and field-market reviews
Meeting pattern: Six boards, monthly Quality Committee during remediation/scale and quarterly Audit
Status: Confidential retained-search specification; client identity only after conflict pre-clearance and NDA.
Anonymised company context
A PE-backed animal-health company developing and manufacturing veterinary vaccines, biologics and diagnostic kits for poultry, dairy and companion-animal markets.
Revenue is ₹1,800–2,600 crore with exports to Asia, Africa and Latin America. A control investor has funded a second biologics facility and bolt-on product acquisitions; an IPO is considered after regulatory approvals and quality-system integration.
Calibrated market hint: Hyderabad biologics capacity, poultry/dairy portfolio and emerging-market exports suggest a small group of animal-health companies. Candidates must treat any inference as confidential and disclose it only for conflict screening.
Why the seat exists now
The board needs an independent director who understands that batch quality, cold-chain, disease claims and country registrations create enterprise risk. Fast portfolio expansion cannot be governed as consumer SKU proliferation.
For a PE-backed business, IPO readiness begins by separating sponsor exit objectives from the legal and commercial interests of the company. Governance must be capable of surviving a change of ownership: related-party economics, acquisition accounting, debt, management incentives, control functions and operating claims need an evidence trail before bankers arrive.
Board design, authority and boundaries
Independent non-executive director; Chair of Board Quality, Biosafety & Risk Committee and Audit member. The member does not release batches or replace the qualified regulatory/quality officers.
The appointee is expected to ask for evidence, frame choices, record dissent and hold management accountable. The appointee is not a part-time executive, broker, operating consultant, fundraiser or representative of the investor who proposed the name. Management remains responsible for execution.
Strategic charter — first 18 months
- Protect quality-unit and biosafety independence from production and sales
- Review master/working seed, cell bank, contamination, batch-failure and cold-chain controls
- Govern pharmacovigilance/adverse-event, field efficacy, complaint and recall decisions by species/product
- Map country registrations, claims, local agents, sanctions and distributor conduct
- Establish acquisition integration for dossiers, IP, inventory, quality agreements and earn-outs
- Review new-plant validation, capacity, yield and commercial-release gates
- Test revenue, government tender, distributor inventory and expiry/return provisioning
- Prepare statutory committees, BRSR/biological risk disclosures, offer-document evidence and management succession before IPO
Decisions likely to reach this director
- Whether a batch or market should be held after an ambiguous field signal
- Whether the second plant is ready for commercial validation
- Whether an acquired dossier can support the claims assumed in valuation
These are not hypothetical interview prompts. They describe the type of decision on which the board expects an independent company-interest view, including the ability to say “not yet,” “only with conditions,” or “stop.”
Candidate market — evidence, not labels
Essential
- Veterinary biologics, vaccines, regulated manufacturing, quality, biosafety, animal health or global regulatory leader
- Board-level patient/animal and commercial judgement
- Plant scale-up experience
- Independence from sponsor and scientific founders
Particularly valuable
- WHO/prequalification or international veterinary approvals
- Contamination/recall governance
- Cold-chain and field pharmacovigilance
- Biologics M&A
- Regulated IPO
The search is deliberately open to former operators, founders, functional leaders, investors with genuine board experience, regulators, academics with operating relevance and experienced directors. Prior service on a listed board is useful but not a proxy for judgement.
IICA Databank and legal eligibility position
This search does not impose IICA Independent Directors Databank registration or the proficiency test as a blanket application gate. The disclosed company is presently private, and the seat is designed as a contractually independent non-executive board role. Before appointment, counsel and the Company Secretary will determine whether the company’s actual legal form, public-company status, holding/subsidiary relationships, borrowing or other facts trigger any statutory independent-director requirement. If the seat is later redesignated as a statutory Independent Director role during conversion or IPO preparation, the appointee must complete every then-applicable requirement before that redesignation.
All candidates must still have a valid DIN before appointment, complete required KYC/consent/disclosures, be free of Section 164 disqualification, remain within applicable Section 165 limits, and satisfy the Articles, shareholders’ agreement, investor consent rights and any sector-specific fit-and-proper rules. “Not required to be in the Databank today” does not mean “unregulated” or “low-liability.”
Independence and conflict screens
Relationships with regulators, distributors, veterinarians, farms, laboratories, licensors, acquired sellers, sponsor or competitors; research/IP self-review; commercial veterinary practice linked to sales.
GILA will map pecuniary, advisory, investment, family, customer, supplier, competitor and investor relationships across the look-back period agreed with counsel. A fund nominee is not automatically independent; a well-known listed-company director is not automatically suitable; and a small equity holding is not automatically harmless. Substance and perception will both be assessed.
Downside diligence offered to the candidate
Before consent, the shortlisted candidate will receive under NDA: the cap table and side letters; Articles and shareholders’ agreement; last six board packs and minutes; cash/runway case; material contracts; regulatory, litigation, IP and related-party schedules; insurance policies; founder/KMP employment and equity terms; latest audit or financial review; whistleblower and incident summary; and a written statement of the expected board/committee classification. The candidate may request independent legal advice through an agreed protocol.
First-year evidence of success
The target is a board and control environment capable of supporting sponsor exit, refinancing or IPO without a last-minute governance rebuild. For this mandate, the board will look for:
- Quality/biosafety decisions are independent and documented
- Facility and acquisition gates close with evidence
- Market claims and distribution inventory are controlled
- IPO diligence sees an integrated quality and regulatory system
Commitment, economics and protection
- Expected commitment: 30–38 days in validation/pre-IPO year.
- Commercial terms: Three-year term with statutory redesignation if legally required. Fixed cash fee and Quality Chair differential; no product/approval success fee. Product, contamination, recall and securities/D&O cover required.
- Minimum protection: a written appointment letter, information and inspection rights, minuting of dissent, a deed of indemnity to the extent legally available, appropriate D&O with advancement and run-off, and access to independent advice.
- No hidden commercial role: no placement fee, sales referral, government liaison, customer introduction or consulting retainer is implied by the board appointment. Any separate engagement would require prior board approval, conflict review and clear disclosure; in many cases it will be prohibited.
Search and appointment process
Conflict pre-clearance → founder and lead-investor conversations held separately → GILA/SYMPHONY™ board-fit assessment → live mandate case → cap-table/SHA and board-pack diligence under NDA → references including one from a difficult company period → joint founder/investor/NRC session → legal, reputation and independence checks → board/shareholder appointment under the constitutional documents.